Upfront Use of 177Lu-Labeled PSMA Radioligand Therapy and Treatment Response Assessment in Treatment-Naive Prostate Cancer

Prostatic malignancy is the most common type of nonskin cancer and associated with significant morbidity and mortality. Early androgen deprivation therapy (ADT) is the treatment of choice in metastatic prostate cancer, whereas ADT delays progression of disease, but it is associated with significant...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical nuclear medicine Vol. 47; no. 2; pp. e167 - e169
Main Authors:	Malik, Dharmender, Sen, Ishita B., Thakral, Parul, Das, Subha Shankar, Manda, Divya, CB, Virupakshappa
Format:	Journal Article
Language:	English
Published:	United States Lippincott Williams & Wilkins 01-02-2022
Subjects:	Androgen Antagonists Humans Male Progression-Free Survival Prostate-Specific Antigen Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant Quality of Life Retrospective Studies Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Prostatic malignancy is the most common type of nonskin cancer and associated with significant morbidity and mortality. Early androgen deprivation therapy (ADT) is the treatment of choice in metastatic prostate cancer, whereas ADT delays progression of disease, but it is associated with significant adverse effects and frequently impairs the quality of life. Therefore, there is growing interest in treatments to postpone ADT while achieving a good progression-free survival. We present a case of oligometastatic prostate cancer, who was treated upfront with 177Lu-labeled PSMA radioligand therapy and demonstrated excellent response to a single dose of 177Lu-PSMA-617.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0363-9762 1536-0229
DOI:	10.1097/RLU.0000000000003890